Kyungpook National University Hospital
Daegu, Dongdeok-ro, 700-721, South Korea
NCT Number: NCT04181437
The purpose of this study is to compare the pharmacokinetics and safety between NVP-1203-R1 and NVP-1203-R2
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Phase 1
Daegu, Dongdeok-ro, 700-721, South Korea
pharmacokinetics and safety between NVP-1203-R1 and NVP-1203-R2
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 tablet, Single oral dosing
Other names: NVP-1203-R1(A)
1 tablet, Single oral dosing
Other names: NVP-1203-R2(E)
NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
Other names: NVP-1203-R1(A) and NVP-1203-R2(E)
Time frame: 0hours - 24hours
Area under the curve (AUC)
NVP Healthcare
Industry
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2 in Healthy Adult Subjects
Acronym: Navipharm
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details